A randomized, open-label, phase II study of lapatinib / capecitabine, lapatinib / vinorelbine, or lapatinib / gemcitabine in patients with ErbB2-amplified metastatic breast cancer progressing after taxane treatment: Results of an interim analysis

01/06/2010

Abstracts, Publications, Publications Breast

(GLICO-0801 / EGF111792).
Henry Leonidas Gomez, Silvia P. Neciosup, Celia Tosello, Patricia Xavier, Yeni Neron do Nascimento, Marcelo Fanelli, Gustavo Ismael, Jose Bines, Carlos Sampaio, Guillermo Luis Lerzo, Adolfo Miguel Capo, Max S. Mano, Luis Fein, Gustavo Werutsky, Carlos H. Barrios
J Clin Oncol 30, 2012 (suppl; abstr e11087)

Full link: https://meetinglibrary.asco.org/record/73652/abstract

A randomized, open-label, phase II study of lapatinib / capecitabine, lapatinib / vinorelbine, or lapatinib / gemcitabine in patients with ErbB2-amplified metastatic breast cancer progressing after taxane treatment: Results of an interim analysis

Send us a message

Cura Project

A randomized, open-label, phase II study of lapatinib / capecitabine, lapatinib / vinorelbine, or lapatinib / gemcitabine in patients with ErbB2-amplified metastatic breast cancer progressing after taxane treatment: Results of an interim analysis

Related Posts

The Lancet Comission on prostate cancer: planning for the surge in cases

Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update

41P – Assessment of rare cancers and sarcoma policy in National Cancer Control Plans (NCCPs) from South American countries: A report from the LACOG Sarcoma Group

1506TiP A single-arm, phase II study of amivantamab (AMI), lazertinib (L) and pemetrexed (P) for first-line treatment of recurrent/metastatic non-small cell lung cancers (NSCLCS) with epidermal growth factor receptor mutations in Exons 19 or 21 (EGFR 19/21): AMIGO 1 (LACOG0821)